ABSTRACT
Background: Guillain-Barré syndrome is a polyradiculoneuropathy that has been associated with infectious diseases as triggers. There is currently little medical evidence exploring the relationship between the development of Guillain-Barré syndrome caused by SARS-CoV-2 infection and long Covid. Objective: To synthesize the medical evidence that describes the relationship between post Covid syndrome and Guillain-Barré syndrome in the paediatric population. Methodology: A scoping review was developed using Scopus and PubMed databases, including analytical and/or descriptive experimental and observational studies. Results: The main clinical manifestations presented by paediatric patients were distal and ascending weakness in the lower limbs and myalgia. The diagnostic approach was based on clinical findings, imaging findings on spinal magnetic resonance and electromyography. The therapeutic strategy is based on the use of intravenous human immunoglobulins. Conclusion: Guillain-Barré syndrome is a frequent disease in the paediatric population with active SARS-CoV-2 infection or in survivors, however, it is necessary to encourage further clinical studies that increase the medical literature that describes this association.
ABSTRACT
Introduction: An increasing number of musculoskeletal clinical manifestations, the onset of diseases and rheumatological manifestations have been seen in the paediatric population surviving COVID-19, however, the medical literature on the subject is limited. Objective(s): To explore the available evidence on musculoskeletal symptoms and autoimmune diseases in the paediatric population with post-COVID syndrome. Methodology: Scoping systematic review in PubMed and Scopus through search strategies. Observational and experimental studies are included in populations under 21 years of age with and without autoimmune diseases, without time limit in English and Spanish. Result(s): The 28 documents included: case reports (n = 6), cross-sectional studies (n = 5), prospective cohort studies (n = 5), retrospective cohort (n = 6), case series (n = 6), ambidirectional section (n = 1), randomized controlled trial (n = 1), and longitudinal section study (n = 1). The total study population was 56,738 patients. The most frequent symptoms presented in long COVID-19 are myalgias and arthralgias. The evidence showing a relationship between SARS-CoV-2 infection in the development of musculoskeletal symptoms and autoimmune diseases in the convalescent period is limited. Conclusion(s): Myalgias and arthralgias are the most frequent symptoms in long COVID. patients with SARS-CoV-2 infection and a history of rheumatic disease who are undergoing immunomodulatory treatment do not have a dangerous risk of developing severe presentations and/or complications of the disease. Copyright © 2022 Asociacion Colombiana de Reumatologia
ABSTRACT
Background: Guillain-Barre syndrome is a polyradiculoneuropathy that has been associated with infectious diseases as triggers. There is currently little medical evidence exploring the relationship between the development of Guillain-Barre syndrome caused by SARS-CoV-2 infection and long Covid. Objective(s): To synthesize the medical evidence that describes the relationship between post Covid syndrome and Guillain-Barre syndrome in the paediatric population. Methodology: A scoping review was developed using Scopus and PubMed databases, including analytical and/or descriptive experimental and observational studies. Result(s): The main clinical manifestations presented by paediatric patients were distal and ascending weakness in the lower limbs and myalgia. The diagnostic approach was based on clinical findings, imaging findings on spinal magnetic resonance and electromyography. The therapeutic strategy is based on the use of intravenous human immunoglobulins. Conclusion(s): Guillain-Barre syndrome is a frequent disease in the paediatric population with active SARS-CoV-2 infection or in survivors, however, it is necessary to encourage further clinical studies that increase the medical literature that describes this association. Copyright © 2022 Asociacion Colombiana de Reumatologia
ABSTRACT
Introduction: SARS-CoV2 infection with severe clinical manifestations has been associated with a decrease in plasma hemoglobin levels. This suggests the need to understand the impact that anemia has in the clinical outcomes of patients with COVID-19.
ABSTRACT
Background: Guillain-Barré syndrome is a polyradiculoneuropathy that has been associated with infectious diseases as triggers. There is currently little medical evidence exploring the relationship between the development of Guillain-Barré syndrome caused by SARS-CoV-2 infection and long Covid. Objective: To synthesize the medical evidence that describes the relationship between post Covid syndrome and Guillain-Barré syndrome in the paediatric population. Methodology: A scoping review was developed using Scopus and PubMed databases, including analytical and/or descriptive experimental and observational studies. Results: The main clinical manifestations presented by paediatric patients were distal and ascending weakness in the lower limbs and myalgia. The diagnostic approach was based on clinical findings, imaging findings on spinal magnetic resonance and electromyography. The therapeutic strategy is based on the use of intravenous human immunoglobulins. Conclusion: Guillain-Barré syndrome is a frequent disease in the paediatric population with active SARS-CoV-2 infection or in survivors, however, it is necessary to encourage further clinical studies that increase the medical literature that describes this association. © 2022 Asociación Colombiana de Reumatología
ABSTRACT
Introduction: Post-traumatic stress disorder occurs among subjects exposed to traumatic or threatening situations. The current COVID-19 pandemic has both physical and mental repercussions for patients. Objective: Explore the current medical evidence on post-COVID-19 post-traumatic stress disorder. M ethodology: Scoping review including databases such as PubMed and Scopus, considering observational studies published in English and Spanish, with data on post-traumatic stress disorder among survivors of SARS-CoV-2 infection. Results: Some 23 documents were included: prospective cohort studies (n = 10), cross-sectional studies (n = 8), retrospective cohort studies (n = 4) and a prospective cohort study and retrospective (n = 1);the total sum of patients evaluated in the studies included in this review was 186 707. Conclusion: Patients surviving COVID-19 present an increased incidence of symptoms such as excessive stress, anxiety, and depressive mood. These symptoms present mostly in patients with a history of mental illness, long hospital stays, and females. © 2022 Academia Nacional de Medicina. All rights reserved.
ABSTRACT
Introduction: Fibromyalgia is a syndrome characterized by chronic generalized pain, joint stiffness, sleep disorders, fatigue, anxiety and depressive episodes, whose clinical manifestations begin after a physical or emotional trauma. However, few publications describe the clinical impact of COVID-19 on fibromyalgia symptoms. Objective: To map the available medical evidence on the impact of COVID-19 and PCS in patients with and without a diagnosis of fibromyalgia prior to infection. Materials and methods: Exploratory systematic review in PubMed and Scopus, considering articles in English and Spanish, with data on fibromyalgia in the population surviving SARS-CoV-2 infection. The clinical trial records of the World Health Organization databases were reviewed. Results: Twelve published articles were included: retrospective studies (n = 4), cross-sectional (n = 2), cases and controls (n = 2), qualitative studies (n = 2), a prospective cohort (n = 1) and a longitudinal section study (n = 1). The total study population of the included publications was 3,060 patients. In addition, one randomized controlled clinical trial and two observational cross-sectional and case-control studies were included. The total sum of the study population was 173 participants. Conclusion: Survivors of COVID-19 with or without a previous diagnosis of fibromyalgia may present an increase in chronic pain, insomnia, joint stiffness, and deterioration in quality of life. The population with a history of fibromyalgia may be more affected by psychological stress, tissue damage to neuromuscular structures, and inflammation due to SARS-CoV-2 infection.
ABSTRACT
Introduction: SARS-CoV2 infection with severe clinical manifestations has been associated with a decrease in plasma hemoglobin levels. This suggests the need to understand the impact that anemia has in the clinical outcomes of patients with COVID-19. Objective: Describe the extent and nature of the scientific publications assessing the relationship between anemia and COVID-19. Methodology: Scoping review including PubMed and Scopus, considering analytic and descriptive observational studies in English and Spanish. Result: 14 publications were found including 29755 patients: retrospective cohort (n=8), prospective cohort (n=3), case control studies (n=1), cross-sectional (n=1) and longitudinal case series (n=1). The authors birthplace was China (n=6), followed by the United States (n=2), Italy (n=1), Greece (n=1), Ethiopia (n=1), South Korea (n=1), Iran (n=1), India (n=1) and Austria (n=1). Conclusion: Anemia is prevalent in SARS-CoV-2 infected patients, mostly in critical clinical presentations. It is associated with long hospitalizations, clinical complications, and deterioration of patient´s survival. © 2021 Instituto de Altos Estudios de Salud Publica. All rights reserved.
ABSTRACT
Introduction: Colchicine is widely used to treat inflammatory diseases such as gout and Mediterranean fever. Due to its immunomodulatory capacity, it could play an important role in the treatment of COVID-19. Objective: To explore the current available medical evidence, published until 28 December 2020, regarding the efficacy and safety of colchicine in the treatment of patients with confirmed SARS-CoV-2 infection. Material and methods: Scoping review of the literature that included PubMed and Scopus. Records of clinical trials and publications with empirical data (observational and experimental studies) in English and Spanish were included. Results: A total of 33 clinical trials and 6 publications were found: prospective (n = 2) and retrospective (n = 2) cohort studies, randomised clinical trials (n = 1) and case-control studies (n = 1). The total number of participants in the trials is 46,324 individuals, 73% (24/33) of the studies are recruiting participants and 51% (17/33) are phase 3 studies. Conclusions: One clinical trial reports a decrease in prognostic inflammatory markers and length of hospital stay in SARS-CoV-2 infection. The ongoing clinical trials will clarify the efficacy and safety of colchicine for the management of patients with COVID-19. © 2021 Asociación Colombiana de Reumatología
ABSTRACT
Introduction: In the absence of a vaccine or specific treatment to control the current pandemic, it is necessary to continue investigating potential therapeutic agents against COVID-19. Traditional Chinese medicine (TCM) has been used in the treatment of patients with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome coronavirus), and may have a role in the prevention, treatment, or rehabilitation of patients with COVID-19. Objective: Describe the current state of the scientific literature published until May 17, 2020 about TCM in the management of patients with COVID-19. Material and methods: Scoping review that included PubMed, Embase, Scopus and 18 databases of the World Health Organization International Registry of Clinical Trials Platforms. Empirical and theoretical publications in English and Spanish were included. Results: A total of 35 documents and 93 clinical trial records (n = 128) were included;46 clinical trials evaluated decoctions, capsules, granules, injections, and oral solutions based on herbal agents. The documents were narrative reviews (n = 9), letters to the editor (n = 6), editorials (n = 3), systematic reviews (n = 4), in silico studies (n = 4), comments (n = 2), case series (n = 2), and clinical practice recommendations (n = 2), clinical practice guidelines (n = 1), in vitro studies (n = 1), and opinion article (n = 1). Conclusions: Only two case series studies using herbal remedies reported benefits for patients with mild and severe SARS-CoV-2 pneumonia. There are 78 ongoing randomized controlled trials that will soon provide evidence on the efficacy and safety of TCM in patients with COVID-19.